Currently out of the existing stock ratings of Vikram Purohit, 64 are a BUY (56.14%), 48 are a HOLD (42.11%), 2 are a SELL (1.75%).

Vikram Purohit

Work Performance Price Targets & Ratings Chart

Analyst Vikram Purohit, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 48.1% that have a potential upside of 40.48% achieved within 158 days.

Vikram Purohit’s has documented 300 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ABSI, Absci Corp at 18-Aug-2025.

Wall Street Analyst Vikram Purohit

Analyst best performing recommendations are on ARQT (ARCUTIS BIOTHERAPEUTICS ).
The best stock recommendation documented was for ARQT (ARCUTIS BIOTHERAPEUTICS ) at 12/21/2023. The price target of $11 was fulfilled within 71 days with a profit of $8.4 (323.08%) receiving and performance score of 45.5.

Average potential price target upside

of $92.93 (76.35%) on TALS (TALARIS THERAPEUTICS).
of $27.87 (59.46%) on RDUS (SCHNITZER STEEL INDUSTRIES).
of $27.65 (27.82%) on ASND (ASCENDIS PHARMA AS).

AXSM Axsome Therapeutics CERT Certara FHTX Foghorn Therapeutics HOOK Hookipa Pharma INCY yte KYMR Kymera Therapeutics RDUS Schnitzer Steel Industries SAGE Sage Therapeutic TALS Talaris Therapeutics TBPH Theravance Biopharma EVLO Evelo Biosciences EXAI Exscientia Ltd ADR TIL Instil Bio RGNX Regenxbio SDGR Schrodinger ARQT Arcutis Biotherapeutics ASND Ascendis Pharma AS AKLI Akili HALO Halozyme Therapeutics BMRN Biomarin Pharmaceutical CMPS Compass Pathways Plc GMAB Genmab AS RXRX Recursion Pharmaceuticals ABVX Abivax SA American Depositary Shares SLRN ACELYRIN, INC. Common Stock ABSI Absci Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jason Gerberry (BAML)